drugset / Trial / NCT05652920
Ori-C101Chimeric Antigen Receptor (CAR) Modified T Cells for the Treatment of HCC
NaSingle-groupOpen-labelTreatment
Summary
This is a Phase I, open-label, multi-center study to assess the safety, pharmacokinetics, and preliminary efficacy of GPC3-directed chimeric antigen receptor modified T cells injection (Ori-C101) in Advanced Hepatocellular Carcinoma(HCC).
Timeline
- Start
- 2022-12-15
- Primary completion
- 2026-12
- Completion
- 2026-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | ORIC-101 | Small molecule | — | Other |